- POSITIVE
Quarterly Revenue Panacea Biotec Sep-2026 Quarterly Revenue is Rs 133 Cr which is growth of 41.0% YoY.
- POSITIVE
Quarterly Net Profit Panacea Biotec Sep-2026 Quarterly Net Profit is Rs 11 Cr which is growth of 168.7% YoY.
356.553.85(1.09%)
131.6K
NSE+BSE Volume
NSE 18 Nov, 2026 3:31 PM
Panacea Biotec quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
Panacea Biotec quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 133.1 | 140.8 | 116.7 | 103.2 | 94.4 | 117.2 | 74 | 111.8 | 80.1 | 60.7 | 96.8 | 98.3 | 96.7 | ||
Operating Exp. | 108.2 | 127.4 | 110.8 | 100.7 | 104.5 | 115.3 | 86.5 | 93 | 69.9 | 67.4 | 89.6 | 88.6 | 84.6 | |
Operating Profit | 18.5 | 7.3 | 0.3 | -1.4 | -13.7 | -3 | -18.6 | 15.4 | 6.7 | -10.5 | -9.2 | 6.6 | 10 | |
Operating Profit Margin % | 14.60% | 5.42% | 0.27% | -1.39% | -15.09% | -2.69% | -27.35% | 14.19% | 8.79% | -18.44% | -11.50% | 6.97% | 10.53% | |
Depr. | 4.5 | 4.5 | 4.2 | 4.9 | 4.9 | 4.8 | 4.9 | 5.2 | 5.1 | 5.1 | 5.1 | 5.2 | 5.3 | |
Interest | 6.3 | 6.9 | 6.3 | 7 | 5.9 | 6 | 4.6 | 3.9 | 3.8 | 3.2 | 3.4 | 3.4 | 3.6 | |
Profit Before Tax | 14.1 | 2 | -4.6 | -9.5 | -20.9 | -8.8 | -22 | 9.7 | 1.3 | -15 | -1.4 | 1.1 | 3.2 | |
Tax | 3.3 | 0.6 | -4.4 | -2.1 | -5.3 | -2.1 | -9.6 | 0 | -1.2 | 0 | 0.6 | |||
Net Profit | 10.8 | 1.4 | -0.2 | -7.4 | -15.6 | -6.7 | -12.4 | 9.7 | 1.3 | -13.8 | -1.4 | 0.4 | 3.2 | |
EPS Adj. latest | 1.8 | 0.2 | -0 | -1.2 | -2.6 | -1.1 | -2 | 1.6 | 0.2 | -2.3 | -0.2 | 0.1 | 0.5 | |
Net profit TTM | 4.6 | -21.8 | -29.9 | -42.1 | -25.1 | -8.2 | -15.2 | -4.2 | -13.4 | -11.5 | 3.6 | -14.8 | -2 | |
Basic EPS TTM | 0.8 | -3.6 | -4.9 | -6.9 | -4.1 | -1.3 | -2.5 | -0.7 | -2.2 | -1.9 | 0.6 | -2.4 | -0.3 | |
Results PDF | ||||||||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Panacea Biotec competitor comparison and performance snapshot within industry
Panacea Biotec revenue mix: sales, profit, and capital employed breakups by segment
Panacea Biotec annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Annual Revenue Panacea Biotec Mar-2026 Annual Revenue is Rs 431 Cr which is growth of 32.2% YoY.
- NEGATIVE
Annual Net Profit Panacea Biotec Mar-2026 Annual Net Profit is Rs -30 Cr which is growth of -96.4% YoY.
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
32.2%
2Y CAGR
5.9%
3Y CAGR
14%
5Y CAGR
3.4%
7Y CAGR
23.3%
10Y CAGR
-4.3%
Total Revenue Annual growth is higher than historical averages.
Operating Exp. Ann.
1Y CHG
36.1%
2Y CAGR
11.7%
3Y CAGR
10.5%
5Y CAGR
4.7%
7Y CAGR
8.5%
10Y CAGR
-2.1%
Operating Expenses Annual Cr growth is higher than historical averages.
Panacea Biotec balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Total Shareholders Fund Panacea Biotec Mar-2026 Total Shareholders Fund is Rs 264 Cr which is growth of -12.0% YoY.
- NEGATIVE
Total Assets Panacea Biotec Mar-2026 Total Assets is Rs 852 Cr which is growth of -2.0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
-5.2% | -11.7% | 263.6 | 299.5 | 313.5 | 309 | 397.6 | 490 | 873.8 | 419.4 | 387.9 | 454.7 | 540 | ||
Minority Interest Liability Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
26.2% | 28.9% | 282 | 196.9 | 169.5 | 140.3 | 95.8 | 79.2 | 72.2 | 91.9 | 590.7 | 727.5 | 793.4 | ||
4.1% | 7.3% | 285.2 | 351.4 | 249 | 253 | 246.8 | 200.8 | 170.6 | 921.1 | 685.3 | 589.9 | 474 | ||
Total Capital Plus Liabilities Ann. | 5.6% | 1.5% | 852.4 | 869.5 | 753.6 | 723.9 | 761.8 | 791.6 | 1,138.5 | 1,442 | 1,673.5 | 1,781.8 | 1,807.4 | |
5.8% | 2.8% | 548.7 | 535.3 | 519.6 | 463.2 | 454.9 | 477.2 | 503 | 499.5 | 928.1 | 969.7 | 1,006.6 | ||
3.1% | 2.6% | 567.9 | 575.7 | 570.4 | 518.8 | 473 | 499 | 524.2 | 525.9 | 1,319.8 | 1,372.4 | 1,468.6 | ||
11.5% | -0.6% | 284.5 | 293.7 | 183.2 | 205.1 | 288.8 | 292.6 | 614.3 | 916.1 | 353.7 | 409.4 | 338.8 | ||
Total Assets Ann. | 5.6% | 1.5% | 852.4 | 869.5 | 753.6 | 723.9 | 761.8 | 791.6 | 1,138.5 | 1,442 | 1,673.5 | 1,781.8 | 1,807.4 | |
Contingent Liabilities plus Commitments Ann. | -12.9% | 0.6% | 424.9 | 381.4 | 377.1 | 643.2 | 372.8 | 411.9 | 368.2 | 407.7 | 428.1 | |||
Bonus Equity Share Capital Ann. | 0% | 0% | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | |
Non Current Investments Unquoted Book Value Ann. | 0% | 0% | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 2.6 | 2.5 | 344.9 | 344.9 | 394.7 | |
Current Investments Unquoted Book Value Ann. | - | - |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Assets Ann.
1Y CHG
-2%
2Y CAGR
6.4%
3Y CAGR
5.6%
5Y CAGR
1.5%
7Y CAGR
-7.2%
10Y CAGR
-7.2%
Total Assets Annual is falling faster than historical averages.
Total Current Liabilities Ann.
1Y CHG
-18.8%
2Y CAGR
7%
3Y CAGR
4.1%
5Y CAGR
7.3%
7Y CAGR
-15.4%
10Y CAGR
-5%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
-12%
2Y CAGR
-8.3%
3Y CAGR
-5.2%
5Y CAGR
-11.7%
7Y CAGR
-6.4%
10Y CAGR
-6.9%
Total ShareHolders Funds Annual is falling faster than historical averages.
Panacea Biotec ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Book Value Per Share Panacea Biotec Mar-2026 Book Value Per Share is 43 Rs which is growth of -9.8% YoY.
- POSITIVE
ROE Panacea Biotec Mar-2026 ROE is -11% which is growth of 6.1% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BVSH Ann. | -4.6% | -11.5% | 43 | 47.7 | 50.2 | 49.6 | 64.2 | 79.4 | 142.2 | 66.8 | 61.8 | 72.9 | 85.4 | |
RoA Ann. % | - | - | -3.50% | -1.75% | 0.47% | -12.09% | -12.28% | -1.82% | -13.44% | 1.84% | -4.29% | -4.07% | 0.04% | |
ROE Ann. % | - | - | -11.34% | -5.20% | 1.15% | -28.79% | -23.78% | -2.96% | -17.57% | 6.49% | -18.99% | -16.28% | 0.16% | |
ROCE Ann. % | - | - | -3.27% | -2.04% | 3.56% | -11.18% | -16.79% | -0.90% | -6.01% | -33.81% | -2.96% | 4.78% | 5.00% | |
Total Debt to Total Equity Ann. | 49.4% | 58.5% | 1 | 0.8 | 0.4 | 0.3 | 0.2 | 0.1 | 0.1 | 0.4 | 2 | 2.1 | 1.9 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Current Ratio Ann.
1Y CHG
25%
2Y CAGR
19.5%
3Y CAGR
7.7%
5Y CAGR
-7.8%
10Y CAGR
3.6%
Current Ratio Annual growth is higher than historical averages.
Panacea Biotec cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Cash From Operating Activity Panacea Biotec Mar-2026 Cash From Operating Activity is Rs -40 Cr which is growth of -1119.4% YoY.
- NEGATIVE
Net Cash Flow Panacea Biotec Mar-2026 Net Cash Flow is Rs -36 Cr which is growth of -208.2% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | -40.2 | 3.9 | 37.3 | -10.7 | -52.7 | 38.3 | -82.9 | 107.2 | 172.1 | 103.8 | 97.9 | ||
Cash from Investing Act. Ann. | - | - | -18.5 | -60.6 | -51 | 2.4 | 39.5 | -37.3 | -18.5 | -8.3 | -2.7 | -17.9 | 22.7 | |
Cash from Financing Act. Ann. | 35.7% | - | 22.5 | 90.1 | 12.8 | 9 | 9.8 | -7.2 | 109.4 | -98.5 | -163.7 | -91.1 | -128.7 | |
- | - | -36.2 | 33.4 | -0.9 | 0.7 | -3.3 | -6.3 | 8 | 0.4 | 5.7 | -5.2 | -8.1 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
-75%
2Y CAGR
32.6%
3Y CAGR
35.7%
Cash from Financing Annual Activity is falling faster than historical averages.
